We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A boost to medical research in next month's Budget, as foreshadowed by Government ministers today, is very welcome and should position Australia well for the future, Medicines Australia said today.
Medical supplier Cardinal Health Inc. on Thursday said its third-quarter profit fell by more than half, hurt by writing off losses from two businesses it plans to sell.
Strong sales of popular blockbuster medicines helped the three biggest drugmakers in the country smash first-quarter profit forecasts on Thursday, underlining a healthy picture for Europe's pharmaceuticals sector.
The World Bank has approved a grant of $180 million to fight malaria in Nigeria, which will focus on promoting malaria-prevention measures and providing the country with more artemisinin combination therapy medications.
A combination of docetaxel, cisplatin, and trastuzumab has shown excellent survival outcomes for patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced breast cancer (LABC), according to a study published in the Journal of Clinical Oncology (JCO).
Ireland-based biotechnology company SuperGen's experimental cancer drug Orathecin has failed to meet the Phase II trial endpoint needed to proceed to a Phase III study, the company announced.
Pharmaceutical company Rexahn has entered into an agreement with Korea-based Future Systems (FS) that will grant FS exclusive rights to develop, manufacture, and sell three of Rexahn's drug candidates in several Korean territories.
PharmEng International Inc., a full-service consulting and contract manufacturing company, today reported its results for the period ended December 31, 2005.
Ranbaxy Laboratories Limited announced on Wednesday that a five-judge panel of the Supreme Patent and Trademark Board of Austria (OPM) has unanimously affirmed an earlier ruling of the Austrian Patent Office, invalidating claims 13 (all claims sought by Ranbaxy to be invalidated) of Pfizer's Austrian Patent AT 207896, covering Atorvastatin calcium (Lipitor).
Vertex Pharmaceuticals Incorporated today announced that researchers will present new data supporting clinical development of VX-950, an investigational oral hepatitis C virus (HCV) protease inhibitor being developed for the treatment of hepatitis C, at the 41st Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna.